Even though there may be some good drugs available, it may take some time until they are more widely accepted, |
Every drug is a balance of benefits and risks, ... With any drug there are risks and you have to be careful with all these drugs in terms of liver damage. No drug is perfect. They're not lollipops. |
For investors in Pfizer, this is a meaningful event. This risk has been a significant overhang for some time. |
I hope they're successful, but the odds are long. |
in the most optimistic scenario. |
It'll be a challenge for [Takeda] by themselves, ... Lilly has historically had a very good presence in the diabetes area. But [Takeda] has got a good drug. |
It's at the margin. It's $3 billion and change of a $50 billion company, so it's not inconsequential, but is it critical to the growth of the company going forward? No. |
It's not very confidence inspiring to pull your guidance, and because of that we're looking hard at our 2006 estimates. |
Pfizer is clearly a winner here. Pfizer is clearly putting their solid foot forward. They've got a good franchise and it's good potential for the next couple years. |
The big drug companies are under duress on almost every front. There are challenges everywhere from generics, from the FDA, from managed care and from self-appointed public watchdogs criticizing the industry, and with attacks on direct-to-consumer advertising, |
The big drug companies are under duress on almost every front. There are challenges everywhere from generics, from the FDA, from managed care and from self-appointed public watchdogs criticizing the industry, and with attacks on direct-to-consumer advertising. |
The earnings guidance may be a bit off-putting to those that were expecting more aggressive projections in 2006. |
The scale of the deal speaks volumes. This is a seminal event in the life of the company. |
We believe that some [PAH] patients are already using the active ingredient for pulmonary arterial hypertension, |
We believe that some [PAH] patients are already using the active ingredient for pulmonary arterial hypertension. |